Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.20.
OMCL has been the subject of a number of research analyst reports. Barclays assumed coverage on Omnicell in a report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price target for the company. Wells Fargo & Company cut their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, February 9th. Finally, Benchmark decreased their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, February 9th.
Get Our Latest Analysis on OMCL
Hedge Funds Weigh In On Omnicell
Omnicell Stock Performance
Shares of OMCL opened at $27.13 on Tuesday. The company has a market capitalization of $1.25 billion, a PE ratio of -60.29 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. Omnicell has a one year low of $25.69 and a one year high of $77.14. The company’s fifty day moving average price is $27.68 and its 200 day moving average price is $32.44.
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The business had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. As a group, analysts expect that Omnicell will post 0.09 earnings per share for the current year.
About Omnicell
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
- Five stocks we like better than Omnicell
- Investing In Automotive Stocks
- Hasbro’s Management Made All the Right Calls This Quarter
- What is the Shanghai Stock Exchange Composite Index?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Pros And Cons Of Monthly Dividend Stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.